Climb Bio Inc (CLYM) - Net Assets
Based on the latest financial reports, Climb Bio Inc (CLYM) has net assets worth $239.55 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($246.29 Million) and total liabilities ($6.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Climb Bio Inc (CLYM) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $239.55 Million |
| % of Total Assets | 97.26% |
| Annual Growth Rate | 40.77% |
| 5-Year Change | -4.02% |
| 10-Year Change | N/A |
| Growth Volatility | 252.32 |
Climb Bio Inc - Net Assets Trend (2019–2025)
This chart illustrates how Climb Bio Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Climb Bio Inc worth.
Annual Net Assets for Climb Bio Inc (2019–2025)
The table below shows the annual net assets of Climb Bio Inc from 2019 to 2025. Also explore Climb Bio Inc annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $160.47 Million | -24.26% |
| 2024-12-31 | $211.88 Million | +96.92% |
| 2023-12-31 | $107.60 Million | -16.41% |
| 2022-12-31 | $128.72 Million | -23.02% |
| 2021-12-31 | $167.20 Million | +675.24% |
| 2020-12-31 | $21.57 Million | +4.64% |
| 2019-12-31 | $20.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Climb Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28225900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $435.00K | 0.27% |
| Other Components | $449.76 Million | 280.27% |
| Total Equity | $160.47 Million | 100.00% |
Climb Bio Inc Competitors by Market Cap
The table below lists competitors of Climb Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thunder Tiger Corp
TW:8033
|
$807.86 Million |
|
United Overseas Australia Ltd
AU:UOS
|
$808.27 Million |
|
Si-Bone Inc
NASDAQ:SIBN
|
$808.53 Million |
|
Shenzhen Anche Technologies Co Ltd
SHE:300572
|
$808.55 Million |
|
Akso Health Group ADR
NASDAQ:AHG
|
$807.33 Million |
|
Jiangsu Nanfang Bearing Co Ltd
SHE:002553
|
$807.27 Million |
|
Standard Foods Corp
TW:1227
|
$807.09 Million |
|
PMB Technology Bhd
KLSE:7172
|
$806.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Climb Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 211,881,000 to 160,475,000, a change of -51,406,000 (-24.3%).
- Net loss of 59,851,000 reduced equity.
- Other comprehensive income increased equity by 412,000.
- Other factors increased equity by 8,033,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-59.85 Million | -37.3% |
| Other Comprehensive Income | $412.00K | +0.26% |
| Other Changes | $8.03 Million | +5.01% |
| Total Change | $- | -24.26% |
Book Value vs Market Value Analysis
This analysis compares Climb Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.95x to 5.94x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.77 | $14.06 | x |
| 2020-12-31 | $1.85 | $14.06 | x |
| 2021-12-31 | $13.64 | $14.06 | x |
| 2022-12-31 | $4.89 | $14.06 | x |
| 2023-12-31 | $3.99 | $14.06 | x |
| 2024-12-31 | $4.40 | $14.06 | x |
| 2025-12-31 | $2.37 | $14.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Climb Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-37.30%) is above the historical average (-42.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -31.76% | 0.00% | 0.00x | 1.04x | $-8.61 Million |
| 2020 | -95.83% | 0.00% | 0.00x | 1.14x | $-22.82 Million |
| 2021 | -28.40% | 0.00% | 0.00x | 1.04x | $-64.20 Million |
| 2022 | -35.15% | 0.00% | 0.00x | 1.05x | $-58.12 Million |
| 2023 | -32.64% | 0.00% | 0.00x | 1.03x | $-45.88 Million |
| 2024 | -34.88% | 0.00% | 0.00x | 1.03x | $-95.09 Million |
| 2025 | -37.30% | 0.00% | 0.00x | 1.05x | $-75.90 Million |
Industry Comparison
This section compares Climb Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Climb Bio Inc (CLYM) | $239.55 Million | -31.76% | 0.03x | $807.55 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary me… Read more